DeutschNewstral
Article
Bbarrons.com on 2019-10-23 12:41
Biogen Stock Climbed on Surprise Alzheimer’s Drug News. The Effects Could Be Lasting.
Related news
- BBiogen Stock Is Soaring as Hope Returns for Alzheimer’s Drugbarrons.com
- BBiogen Stock Could Have Run Up Too Far on Alzheimer’s Drug Revivalbarrons.com
Biogen applies to market Alzheimer’s disease treatment in the USNew York Post
Biogen CEO: ‘Major bottleneck’ still limits Alzheimer’s drugSeattle Times- BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min readbarrons.com
Biogen Submits Promising Alzheimer’s Drug Aducanumab to FDA for Approvalobserver.com
Biogen cuts the price for its Alzheimer’s drug in halfpressherald.com- FFDA approves Biogen Alzheimer’s drugft.com
- BBiogen Earnings Were Good, but an Alzheimer’s Drug Delay Hits Sharesbarrons.com
- BBiogen Is Spiking Because Its Alzheimer’s Drug Takes Another Step Toward Approvalbarrons.com
- BAfter Lengthy Delay, Biogen Submits Troubled Alzheimer’s Drug for FDA Approvalbarrons.com
Biogen Sees Heavy Patient Interest in New Alzheimer’s Drug4 min readwsj.com
Panels find FDA, Biogen rushed Alzheimer’s drugArkansas Online
Biogen Abandons Its Controversial Alzheimer’s Drug AduhelmWRAL- MAll eyes will be on Biogen Alzheimer’s results this week — and the stock could swing wildlymarketwatch.com
- MAlzheimer’s expert says more clinical trials are needed for controversial Biogen drugmarketwatch.com
- TBiogen Stock Soars On Promising Data From Late-Stage Alzheimer’s Drug Trialthestreet.com
- Biogen cuts the price tag on its Alzheimer’s drug in halfSeattle Times
- HBiogen Cuts the Price Tag on its Alzheimer’s Drug in Halfhamodia.com